The
Indian pharmaceutical market will continue to grow in the double
digits, representing a better growth opportunity than many other
geographic markets, Moody's Investors Service says. However, drug
companies in the country could face higher debt levels as the
pharmaceutical sector grows, resulting in mergers and acquisitions,
it said. "As consolidation in the industry continues globally,
particularly among generic drug companies, Indian firms will
increasingly look to become involved in global mergers and
acquisitions. We have already seen some Indian companies increasing
their pace of acquisitions," Moody's senior vice president
Michael Levesque said in a report here. "Even if India's GDP
growth slows or is uneven, the Indian pharmaceutical market would
still represent a better growth opportunity than many other
geographic markets, because of improving socioeconomic conditions and
access to health care, against the backdrop of a rising prevalence of
diseases such as diabetes and cardiovascular problems," Moody's
vice president and senior analyst Kailash Chhaya said. While Indian
firms do not face the same growth pressures as other players across
the industry, they could become involved in global merger and
acquisition activities; thereby pressuring their leverage from
currently low levels. However, for most Indian companies, debt
headroom is large as balance sheets are generally lowly leveraged.
Moody's report acknowledges that as a general rule, key Indian
players have maintained low financial leverage and demonstrated their
aversion to risk, due to their unique structures -- when compared
with global pharmaceutical firms -- of high ownership levels by
founding family members, known as promoters.
Moody's
sees such structures as credit positive for Indian drug companies,
because the interests of creditors and promoters are frequently
aligned and often lead to a more cautious risk appetite. The report
acknowledges that size alone does not drive credit quality. Indian
drug companies are characterised by good geographic diversity,
healthier growth outlooks and more conservative financial policies
than compared to large global players. Indian firms also exhibit
favourable geographic mix, because of their strong presence in
emerging markets like India and Russia, which will see high growth.
By contrast, leading players in the mature, highly competitive US and
western European markets, demonstrate much higher revenue
concentration. According to Moody's, the US market represents a
substantial growth opportunity for Indian drug companies, due to the
rich pipelines of generic drugs awaiting approval by the US Food and
Drug Administration. However, considerable event risk results from
FDA manufacturing compliance standards, which have resulted in
numerous warning letters for plants operated by Indian companies, it
added. In addition, generic players operating in the US market will
see greater exposure to legal costs, owing to new rules that will
make companies responsible for drug safety labelling, Moody's said.
No comments:
Post a Comment